|
JP2020059741A
|
|
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
|
US2020155521A1
|
|
Pharmaceutical combination for treatment of cancer
|
|
TW202024087A
|
|
Solid forms of tetrahydropyranyl amino-pyrrolopyrimidinone compounds
|
|
US2018055846A1
|
|
Amino-pyrrolopyrimidinone compounds and methods of use thereof
|
|
SG11201804670PA
|
|
Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
|
|
AU2016369520A1
|
|
Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
|
|
TW201722956A
|
|
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
|
US9630968B1
|
|
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
|
WO2017111787A1
|
|
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
|
TW202033200A
|
|
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
|
SG10201912615PA
|
|
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
|
CN111494378A
|
|
Compositions and methods for treating proliferative disorders
|
|
CN106795153A
|
|
The salt and polymorphic of substituted imidazopyridyl aminopyridine compounds
|
|
US2015266876A1
|
|
Process of preparing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-B]pyridin-2-yl)pyridin-2-amine
|
|
US2014275023A1
|
|
Substituted tricyclic pyrazolo-pyrimidine compounds
|
|
AU2013252944A1
|
|
Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same
|
|
MX2014000253A
|
|
Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same.
|
|
KR20140040773A
|
|
Substituted imidazopyridinyl-aminopyridine compounds
|
|
WO2012177852A1
|
|
Substituted imidazopyridinyl compounds
|
|
TW201307346A
|
|
Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
|
